<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02287493</url>
  </required_header>
  <id_info>
    <org_study_id>PV4244</org_study_id>
    <nct_id>NCT02287493</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Selected Antiinfectives During Sustained Low-efficiency Dialysis (SLED)</brief_title>
  <acronym>PhA-SLED</acronym>
  <official_title>Pharmacokinetics of Selected Antiinfectives During Sustained Low-efficiency Dialysis (SLED)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a prospective, non-interventional, monocentric observational study the pharmacokinetic&#xD;
      properties of selected antiinfective drugs during sustained low-efficiency dialysis (SLED)&#xD;
      will be analyzed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antibiotic concentrations are measured whilst patients receive SLED for renal replacement&#xD;
      therapy. The plasma specimens will be quantified using high Performance liquid chromatography&#xD;
      (HPLC).&#xD;
&#xD;
      Primary endpoint:&#xD;
&#xD;
      - Plasma levels of antiinfectives during SLED&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        -  mortality&#xD;
&#xD;
        -  length of stay at the intensive care unit (ICU) and hospital&#xD;
&#xD;
        -  clinical cure of infections&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
        -  age: &gt; 18 years&#xD;
&#xD;
        -  patients under SLED&#xD;
&#xD;
        -  antiinfective treatment&#xD;
&#xD;
      exclusion criteria:&#xD;
&#xD;
      - missing informed consent&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2013</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patients Showing Serum Levels of Meropenem or Ceftazidim at the End of SLED Above the Minimal Inhibitory Concentration (MIC)</measure>
    <time_frame>days receiving SLED</time_frame>
    <description>Plasma concentrations of meropenem or ceftazidim by the end of SLED therapy. Meropenem and ceftazidim are often used for empirical treatment also targeting for Pseudomonas aeruginosa (PSA) infections.&#xD;
Therefore, minimal targeted concentrations were set to the MIC of 2 mg/l for meropenem and to the MIC of 4 mg/L for ceftazidime treatment according to the breakpoints of PSA strains.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>minimum duration of hospital stay, maximum 1 year</time_frame>
    <description>ICU mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay (LOS)</measure>
    <time_frame>minimum duration of hospital stay, maximum 1 year</time_frame>
    <description>Length of stay at the ICU and in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Cure of Infections</measure>
    <time_frame>minimum duration of hospital stay, maximum 1 year</time_frame>
    <description>Clinical response to antibiotic treatment assessed by laboratory parameters such as leucocyte count, c-reactive protein or procalcitonin levels as well as vasopressor support</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">35</enrollment>
  <condition>Replacement Therapy, Renal</condition>
  <arm_group>
    <arm_group_label>Meropenem</arm_group_label>
    <description>Adult ICU patients receiving meropenem during SLED will be analyzed for meropenem pharmacokinetics.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ceftazidim</arm_group_label>
    <description>Adult ICU patients receiving ceftazidim during SLED will be analyzed for ceftazidim pharmacokinetics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacokinetic Analysis</intervention_name>
    <arm_group_label>Ceftazidim</arm_group_label>
    <arm_group_label>Meropenem</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult ICU patients at University Medical Center Hamburg-Eppendorf receiving SLED and either&#xD;
        meropenem or ceftazidim.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age: 18 or older&#xD;
&#xD;
          -  patients receiving SLED and either meropenem or ceftazidim&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  missing informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Kluge, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Hamburg-Eppendorf, Department of Intensive Care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 30, 2014</study_first_submitted>
  <study_first_submitted_qc>November 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2014</study_first_posted>
  <results_first_submitted>November 10, 2020</results_first_submitted>
  <results_first_submitted_qc>January 31, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 18, 2021</results_first_posted>
  <last_update_submitted>January 31, 2021</last_update_submitted>
  <last_update_submitted_qc>January 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsklinikum Hamburg-Eppendorf</investigator_affiliation>
    <investigator_full_name>Stefan Kluge</investigator_full_name>
    <investigator_title>Director of the Department of Intensive Care</investigator_title>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Meropenem</title>
          <description>Adult ICU patients receiving meropenem during SLED will be analyzed for meropenem pharmacokinetics.</description>
        </group>
        <group group_id="P2">
          <title>Ceftazidim</title>
          <description>Adult ICU patients receiving ceftazidim during SLED will be analyzed for ceftazidim pharmacokinetics.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Meropenem</title>
          <description>Adult ICU patients receiving meropenem during SLED will be analyzed for meropenem pharmacokinetics.</description>
        </group>
        <group group_id="B2">
          <title>Ceftazidim</title>
          <description>Adult ICU patients receiving ceftazidim during SLED will be analyzed for ceftazidim pharmacokinetics.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="52" upper_limit="74"/>
                    <measurement group_id="B2" value="63" lower_limit="56" upper_limit="67"/>
                    <measurement group_id="B3" value="64.5" lower_limit="33" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patients Showing Serum Levels of Meropenem or Ceftazidim at the End of SLED Above the Minimal Inhibitory Concentration (MIC)</title>
        <description>Plasma concentrations of meropenem or ceftazidim by the end of SLED therapy. Meropenem and ceftazidim are often used for empirical treatment also targeting for Pseudomonas aeruginosa (PSA) infections.&#xD;
Therefore, minimal targeted concentrations were set to the MIC of 2 mg/l for meropenem and to the MIC of 4 mg/L for ceftazidime treatment according to the breakpoints of PSA strains.</description>
        <time_frame>days receiving SLED</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Meropenem</title>
            <description>Adult ICU patients receiving meropenem during SLED will be analyzed for meropenem pharmacokinetics.&#xD;
Pharmacokinetic Analysis</description>
          </group>
          <group group_id="O2">
            <title>Ceftazidim</title>
            <description>Adult ICU patients receiving ceftazidim during SLED will be analyzed for ceftazidim pharmacokinetics.&#xD;
Pharmacokinetic Analysis</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Showing Serum Levels of Meropenem or Ceftazidim at the End of SLED Above the Minimal Inhibitory Concentration (MIC)</title>
          <description>Plasma concentrations of meropenem or ceftazidim by the end of SLED therapy. Meropenem and ceftazidim are often used for empirical treatment also targeting for Pseudomonas aeruginosa (PSA) infections.&#xD;
Therefore, minimal targeted concentrations were set to the MIC of 2 mg/l for meropenem and to the MIC of 4 mg/L for ceftazidime treatment according to the breakpoints of PSA strains.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Trough level &lt; MIC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trough level &gt; MIC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>ICU mortality</description>
        <time_frame>minimum duration of hospital stay, maximum 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Meropenem</title>
            <description>Adult ICU patients receiving meropenem during SLED will be analyzed for meropenem pharmacokinetics.&#xD;
Pharmacokinetic Analysis</description>
          </group>
          <group group_id="O2">
            <title>Ceftazidim</title>
            <description>Adult ICU patients receiving ceftazidim during SLED will be analyzed for ceftazidim pharmacokinetics.&#xD;
Pharmacokinetic Analysis</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>ICU mortality</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Stay (LOS)</title>
        <description>Length of stay at the ICU and in hospital</description>
        <time_frame>minimum duration of hospital stay, maximum 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Meropenem</title>
            <description>Adult ICU patients receiving meropenem during SLED will be analyzed for meropenem pharmacokinetics.</description>
          </group>
          <group group_id="O2">
            <title>Ceftazidim</title>
            <description>Adult ICU patients receiving ceftazidim during SLED will be analyzed for ceftazidim pharmacokinetics.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Stay (LOS)</title>
          <description>Length of stay at the ICU and in hospital</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LOS in hospital</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="24" upper_limit="264"/>
                    <measurement group_id="O2" value="90" lower_limit="15" upper_limit="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LOS in ICU</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="8" upper_limit="264"/>
                    <measurement group_id="O2" value="67" lower_limit="12" upper_limit="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Cure of Infections</title>
        <description>Clinical response to antibiotic treatment assessed by laboratory parameters such as leucocyte count, c-reactive protein or procalcitonin levels as well as vasopressor support</description>
        <time_frame>minimum duration of hospital stay, maximum 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Meropenem</title>
            <description>Adult ICU patients receiving meropenem during SLED will be analyzed</description>
          </group>
          <group group_id="O2">
            <title>Ceftazidim</title>
            <description>Adult ICU patients receiving ceftazidim during SLED will be analyzed</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cure of Infections</title>
          <description>Clinical response to antibiotic treatment assessed by laboratory parameters such as leucocyte count, c-reactive protein or procalcitonin levels as well as vasopressor support</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious, and Other (not including serious) Adverse Events were not monitored/ assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Meropenem</title>
          <description>Adult ICU patients receiving meropenem during SLED will be analyzed for meropenem pharmacokinetics.</description>
        </group>
        <group group_id="E2">
          <title>Ceftazidim</title>
          <description>Adult ICU patients receiving ceftazidim during SLED will be analyzed for ceftazidim pharmacokinetics.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Christina König</name_or_title>
      <organization>University Medical Center Hamburg-Eppendorf</organization>
      <phone>+49 040 7410 -0</phone>
      <email>ch.koenig@uke.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

